Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249558 | 0.97 | ADORA2B (0.49) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL4250791 | 0.91 | SIRT1 (0.51) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4249256 | 0.85 | ADORA2A (0.46) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4256241 | 0.84 | ADORA2B (0.46) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL4259058 | 0.83 | PDE4A (0.53) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL837990 | 0.79 | ADORA2B (0.52) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL3123746 | 0.79 | ADORA2B (0.52) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL837398 | 0.77 | ADORA2B (0.52) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL836739 | 0.74 | ADORA1 (0.57) | ADORA2BADORA1ADORA3ADORA2APDE4A | |
| SCHEMBL4252239 | 0.74 | PDE4A (0.51) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| EP-1805180-A1 | XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY | SmithKline Beecham Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045565-A1 | XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | XDH, HCAR1, GPR84 | ADORA2B 131/4885ADORA1 24/4885ADORA3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.